Mittelman A, Wang X, Matsumoto K, Ferrone S
Department of Medicine, New York Medical College, Valhalla 10595, USA.
Hybridoma. 1995 Apr;14(2):175-81. doi: 10.1089/hyb.1995.14.175.
An active specific immunotherapy trial has been implemented in patients with malignant melanoma utilizing the mouse anti-id MAb MK2-23. The latter bears the internal image of the determinant by the anti-HMW-MAA MAb 763.74. The immunogenicity of anti-id MAb MK2-23 is enhanced by conjugation to a carrier and administration with an adjuvant. Anti-id MAb MK2-23 induced humoral anti-HMW-MAA immunity in about 60% of the immunized patients. The latter was associated with a statistically significant survival prolongation. It is suggested that anti-HMW-MAA immunity may have a beneficial effect on the clinical course of the disease by inhibiting the function of HMW-MAA in the biology of melanoma cells.
一项针对恶性黑色素瘤患者的主动特异性免疫疗法试验已经开展，该试验使用了小鼠抗独特型单克隆抗体MK2-23。后者具有抗高分子量黑色素瘤相关抗原（HMW-MAA）单克隆抗体763.74所识别的决定簇的内影像。抗独特型单克隆抗体MK2-23与载体偶联并与佐剂一起给药后，其免疫原性增强。抗独特型单克隆抗体MK2-23在约60%的免疫患者中诱导出了体液抗HMW-MAA免疫。后者与具有统计学意义的生存期延长相关。有人提出，抗HMW-MAA免疫可能通过抑制HMW-MAA在黑色素瘤细胞生物学中的功能，对疾病的临床进程产生有益影响。
